| Stereochemistry | ABSOLUTE |
| Molecular Formula | C30H48O3 |
| Molecular Weight | 456.7003 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@@H](O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C
InChI
InChIKey=NBGQZFQREPIKMG-PONOSELZSA-N
InChI=1S/C30H48O3/c1-18-10-13-26(3)16-17-28(5)20(24(26)19(18)2)8-9-21-27(4)14-12-23(31)30(7,25(32)33)22(27)11-15-29(21,28)6/h8,18-19,21-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19+,21-,22-,23-,24+,26-,27-,28-,29-,30-/m1/s1
Β-boswellic acid (β-BA) is one of the active triterpenoid compounds from the extract of boswellia serrate, known in Indian Ayurvedic system of medicine as Salai guggal. Beta-boswellic acid has been indicated in apoptosis of cancer cells. β-boswellic acid belonds to class of boswellic acids exhibiting anti-inflammatory activities, which are in the phase II clinical trial for study of safety and tolerability in subjects with Relapsing Remitting Multiple Sclerosis.
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
8 months of treatment at three times a day dose of between 400-1600 mg
Route of Administration:
Oral
β-boswellic acid (β-BA) significantly increases nitric oxide (NO) production in human umbilical vein endothelial cells (HUVECs). HEUVCs were pretreated with β-BA (25 and 50 uM) for 24 h before being subjected to 6 h OGD then incubated with β-BA for an additional 24 h. NO production was measured by DAF-FM DA. The amount of NO was evaluated by measuring the fluorescence intensity excited at 495 nm and emitted at 515 nm.
SUBSTANCE RECORD
